Future studies focusing on the pharmacodynamic effect of incretin hormones or using methodology that will capture the biologically active GLP‐1 will be required to ascertain the effect that FMT might have on canine incretin hormones in diabetes. This evidence concerns the gene GCG and diabetes mellitus.